Navigation Links
FDA Selects CreatiVasc For New Innovation Pathway Program
Date:4/9/2012

GREENVILLE, S.C., April 9, 2012 /PRNewswire-USNewswire/ -- Greenville-based CreatiVasc Medical has been selected as one of the first three companies for the FDA's new Innovation Pathway program that uses collaboration with innovators to speed important medical devices to market while safeguarding patient safety.

The company has developed an innovative device for dialysis patients, called the Hemoaccess Valve System®, which has the potential to significantly reduce the complications, costly interventional surgery and suffering associated with End Stage Renal Disease patients on dialysis.

The valve system device is now in Phase I human clinical trials. Unlike current dialysis-access graft devices which are prone to clotting and early failure, the CreatiVasc technology is implanted when a patient's access graft is created and allows blood flow to be turned on through the patient's graft only when it is needed for dialysis, then turned off afterward. CreatiVasc and FDA will begin their collaboration in early May.

Company officials said the device could be on the market and available for patients within 24 months.

End Stage Renal Disease, the focus of the first Innovation Pathway, affects more than 571,000 Americans and is considered one of the most costly chronic diseases. Kidney failure and associated dialysis cost the U.S. healthcare system more than $46 billion annually.

Many dialysis patients have a Teflon tube implanted in their arm to provide vascular access for dialysis. Such tubes present a constant challenge because they frequently clot and require costly interventional surgery. According to a study published in the New England Journal of Medicine, more than 75% of dialysis grafts fail and require surgical intervention within the first year after placement. Early research shows that the CreatiVasc Hemoaccess Valve System allows selective blood flow into these grafts only when it is needed for dialysis, which is believed to reduce such universal complications.

The new FDA program will provide a totally new way for medical device companies and FDA to collaborate to assure that promising new technologies are rigorously reviewed but are also guided through its device approval process as rapidly as possible without compromising patient safety.

CreatiVasc was founded in Greenville, S.C., in 2004 by Dr. David Cull, a vascular surgeon with the Greenville Hospital System who developed the new technology after seeing first-hand the problems associated with traditional dialysis-access grafts. The company began full-time operations in 2007. The company has multiple issued patents on the device both in the U.S. and around the world.


'/>"/>
SOURCE Greenville Hospital System
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Weill Cornell Medical College Selects Ingenuity® Variant Analysis™ and Ingenuity® iReport™ for Sequencing Core Facility
2. ASLAN Pharmaceuticals Selects PharmaNet/i3 as Strategic Partner For Oncology Development
3. Rubicon Genomics Selects Velesco to Manufacture its TransPLEX® RNA Amplification Kits for Clinical Diagnostic Use
4. Stryker Communications Selects Glowpoint to Enhance IP Video Platform for Operating Rooms
5. NorthCrest Medical Center Selects Allscripts Sunrise Electronic Health Record
6. Biotechnology Pharmaceutical Company Selects NewCardios QTinno for Thorough QT Trial
7. Mental Health Partners Selects Stockell Healthcares InsightCS® Revenue Cycle Information Management System
8. Global Pharma Selects Semantellis Compliance Ready Social Listening Platform to Manage Corporate Reputation
9. Mammoth Hospital Selects Allscripts RCM Services
10. Inova Selects Beryl as Provider of Outsourced Patient Experience Solutions
11. WHCA Selects COMS Interactive as Affinity Partner
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... 2017  Abaxis, Inc. (NasdaqGS: ABAX ), ... and consumables for the medical and veterinary markets worldwide, ... results for the third quarter fiscal year 2017, ended ... p.m. ET on Thursday, January 26, 2017.  The Company ... year 2017 after the market closes on Thursday, January ...
(Date:1/19/2017)... -- ViewRay, Inc. (Nasdaq: VRAY) announced today that the German ... Germany , has purchased a MRIdian ... Clinic Heidelberg as part of its initiative for MRI-based ... be headed by Medical Director and Professor Jürgen Debus, ... German Cancer Research Center (DKFZ), the Heidelberg Heavy Ion ...
(Date:1/19/2017)... England , January 19, 2017 ... and Otsuka in the Milner Therapeutics Consortium   ... scientists in Cambridge   ... (NYSE: PFE ) as a partner to ... the Consortium, which enables the efficient transfer of materials ...
Breaking Medicine Technology:
(Date:1/19/2017)... ... January 19, 2017 , ... ... panel system. , The Tranquility privacy panel system was designed to deliver ... Tranquility panels help reduce noise and provide the visual privacy required to maintain ...
(Date:1/19/2017)... ... ... Allegheny Health Network (AHN) officials today announced a bold new step to ... services in the greater Pittsburgh region. Starting January 23, patients who call AHN by ... same afternoon. , AHN is the first healthcare provider in the ...
(Date:1/19/2017)... GA (PRWEB) , ... January 19, 2017 , ... ... offers asset protection and financial planning services to communities throughout eastern Georgia, is ... fight against heart disease. , Heart disease kills more Americans every year than ...
(Date:1/19/2017)... NJ (PRWEB) , ... January 19, 2017 , ... ... locally owned insurance agency which serves Lawrenceville, New Jersey and the surrounding area, ... , Amyotrophic lateral sclerosis (ALS), more commonly known as Lou Gehrig's disease ...
(Date:1/19/2017)... ... 19, 2017 , ... Attorney Robert “RC” Pate , founder of The ... the Triumph Over Kid Cancer foundation. Each year, 175,000 children are diagnosed with pediatric ... firsthand the effect of the critical funding gap for research into pediatric cancer research. ...
Breaking Medicine News(10 mins):